ClinicalTrials.Veeva

Menu
U

University Medical Center Groningen | Dermatology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

MK-7962
Vericiguat
MK-6482
Belzutifan
MK-7962-008
MK-1242-036
Sotatercept
Pembrolizumab

Parent organization

This site is a part of University Medical Center Groningen

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 3 total trials

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Belzutifan
Biological: Pembrolizumab

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline t...

Enrolling
Left Ventricular Systolic Dysfunction
Heart Failure
Drug: Vericiguat tablet
Drug: Placebo tablet

The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment...

Enrolling
Pulmonary Arterial Hypertension
Drug: Sotatercept

Trial sponsors

Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems